Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy-Reference-Cited by-同舟云学术

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy

Published:2009-07-02 Issue:14 Volume:69 Page:1579-1585
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Kuroda Kenji,Liu He,Kim Sae,Guo Ming,Navarro Vincent,Bander Neil H.

Publisher

Wiley

Subject

Urology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pros.21004/fullpdf

Reference20 articles.

1. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

2. TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer;Oudard;J Clin Oncol,2005

4. Cancer and Leukemia Group B (CALGB). The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study;Kornblith;Ann Oncol,2001

5. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits;Moos;Cell Growth Differ,1998

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study;Clinical Genitourinary Cancer;2024-04

2. Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer?;Seminars in Nuclear Medicine;2024-01

3. Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer;British Journal of Cancer;2023-09-06

4. A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling;Molecular Cell;2023-08

5. Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer;Cancers;2023-06-23